Biophagy is awarded a second NMSBA leverage grant with Sandia National Laboratories to lead a team of three companies (including Avisa Pharma and Omphalos Biosciences) towards identifying a lead autophagy stimulant in tuberculosis. The team will be working with human TB bacteria (M. tuberculosis, attenuated) and human macrophages to determine the effects of autophagy on isoniazid antibiotic enhancement and on U-TAID (proprietary antibiotic). They will also use an siRNA knockdown cell line to delineate the direct role of autophagy in compound activity and antibiotic enhancement. By jordan|2022-03-22T20:38:18+00:00February 1, 2022|2019-announcements|0 Comments Read More
Biophagy initiates a collaboration with Dr. Karin High, UNM, to study its proprietary compounds in chronic neuropathic pain, in vivo. By jordan|2022-02-01T19:09:54+00:00February 1, 2022|2018-announcements|0 Comments Read More
Biophagy is awarded a New Mexico Small Business Assistance (NMSBA) leverage grant with Sandia National Laboratories to lead a team of four companies (including Avisa Pharma, PureInfo Discovery, and Omphalos Biosciences) to investigate binding dynamics of several proprietary autophagy stimulants on cytoskeleton and lysosome movement. They will also study compound enhancement of antibiotic killing using M. bovis, in mouse macrophages. This is a surrogate assay for tuberculosis. By jordan|2022-03-22T20:38:46+00:00February 1, 2022|2018-announcements|0 Comments Read More
Biophagy announces the addition of Ian Henderson, PhD, as its head of medicinal chemistry By jordan|2022-02-01T19:09:25+00:00February 1, 2022|2017-announcements|0 Comments Read More
Biophagy, working with Sandia National Laboratories, is awarded an individual company grant from NMSBA to study the relative potencies and binding sites of several autophagy stimulant combinations. By jordan|2022-03-22T20:39:10+00:00February 1, 2022|2017-announcements|0 Comments Read More
Biophagy, working with Sandia National Laboratories, is awarded an individual company grant from NMSBA to study the binding sites and autophagy stimulating activities of several UNM compounds under consideration for licensing. By jordan|2022-03-22T20:39:42+00:00February 1, 2022|2016-announcements|0 Comments Read More
Biophagy opens a second office in Mountainair, NM By jordan|2022-02-01T19:08:54+00:00February 1, 2022|2016-announcements|0 Comments Read More
Albuquerque Business First awards Dr. Mary Ortner, Biophagy’s CEO, its Woman of Influence award in recognition of her contributions to business development in Albuquerque. By jordan|2022-03-22T20:40:02+00:00February 1, 2022|2016-announcements|0 Comments Read More
Biophagy, working with Sandia National Laboratories, receives an individual company grant from New Mexico Small Business Assistance (NMSBA) to investigate curcumin and resveratrol analogs for autophagy activity. By jordan|2022-03-22T20:40:32+00:00February 1, 2022|2015-announcements|0 Comments Read More
Biophagy changes its corporate structure from LLC to Inc. By jordan|2022-02-01T19:08:23+00:00February 1, 2022|2015-announcements|0 Comments Read More